France Pain Management Drugs Market Size, Share, Opportunities, And Trends By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Acetaminophen, Opioid (Strong Opioid, Weak Opioid), Antidepressants, Anticonvulsant Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Cancer, Rheumatoid Arthritis, Chronic Back Pain, Post-Operative Pain, Others), And By Regions - Forecasts From 2025 To 2030

France Pain Management Drugs Market Size:

France pain management drugs market is anticipated to grow at a CAGR of 2.11% from 2025 to 2030.

The demand for pain management drugs in France is being driven by the rising prevalence of chronic diseases, growing cases of cancer, chronic back pain, and arthritis among others. The well-developed healthcare sector is also one of the major factors that augment the demand for pain management drugs in the country. This is bringing in significant support from the government in this country.

Likewise, the majority of total health expenditure is funded by the government on account of growing concerns regarding the burden of rising out-of-pocket expenditure, particularly among people without any good complementary health insurance. This is increasing the adoption of advanced healthcare services among people which also includes treatment of major chronic diseases and costly surgical procedures as well, which is anticipated to drive the demand for pain management drugs in the country, thereby boosting the market growth. Hence, initiatives such as Complementary Health Insurance (CHI) offered by the French government also financial protection for the population.

The growing strength of the old-age population has further escalated the prevalence of body-pain-related issues such as chronic back pain and rheumatoid arthritis in France. According to the European Commission, the total population of France is set to grow from 68.05 million in 2022 to 69.453 million by 2030 and 70.623 million by 2050. Hence, during such a time frame the old-age dependency ratio of the population aged 65 years and above is expected to increase from 38.2% in 2020 to 53.2% by 2050.

Likewise, according to the “Health at Glance 2024 Europe” issued by the European Commission, more than 40% of the French population aged 65 years and above suffers from at least chronic disease which further increases their scale of physical inactivity due to high levels of body pain. Additionally, the ongoing investment in bolstering pharmaceutical production and improving the frequency of over-the-counter medicines for generic purposes has established a new framework for pain management drug sales in the French market. Hence major market players namely Novartis Pharmaceutical Corporation, Pfizer Inc, GlaxoSmithKline Plc, and Sanofi S.A. offer an extensive portfolio to meet the consumer requirement for varied body pain acting as an additional driving factor for market growth at the country level.

France Pain Management Drug Market Segmentation

• By Drug Type
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Acetaminophen
  • Opioid
    • Strong Opioid
    • Weak Opioid
  • Antidepressants
  • Anticonvulsant Drugs
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Indication
  • Cancer
  • Rheumatoid Arthritis
  • Chronic Back Pain
  • Post-Operative Pain
  • Others
• By City
  • Paris
  • Marseille
  • Lyon
  • Toulouse
  • Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. FRANCE PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction

5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Acetaminophen

5.5. Opioid

5.5.1. Strong Opioid

5.5.2. Weak Opioid

5.6. Antidepressants

5.7. Anticonvulsant Drugs

5.8. Others

6. FRANCE PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Hospital Pharmacies

6.3. Retail Pharmacies 

6.4. Online Pharmacies

7. FRANCE PAIN MANAGEMENT DRUGS MARKET BY INDICATION

7.1. Introduction

7.2. Cancer

7.3. Rheumatoid Arthritis

7.4. Chronic Back Pain

7.5. Post-Operative Pain

7.6. Others

8. FRANCE PAIN MANAGEMENT DRUGS MARKET BY CITY

8.1. Introduction

8.2. Paris

8.2.1. By Drug Type

8.2.2. By Distribution Channel

8.2.3. By Indication

8.3. Marseille

8.3.1. By Drug Type

8.3.2. By Distribution Channel

8.3.3. By Indication

8.4. Lyon

8.4.1. By Drug Type

8.4.2. By Distribution Channel

8.4.3. By Indication

8.5. Toulouse

8.5.1. By Drug Type

8.5.2. By Distribution Channel

8.5.3. By Indication

8.6. Others

8.6.1. By Drug Type

8.6.2. By Distribution Channel

8.6.3. By Indication

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Novartis Pharmaceuticals Corporation (Novartis AG)

10.2. Eli Lilly and Company

10.3. Pfizer Inc.

10.4. GlaxoSmithKline plc

10.5. Merck & Co., Inc.

10.6. Sanofi S.A

10.7. Johnson & Johnson

10.8. Viatris Inc.

10.9. Grünenthal 

10.10. The Menarini Group

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

Novartis Pharmaceuticals Corporation (Novartis AG)

Eli Lilly and Company

Pfizer Inc.

GlaxoSmithKline plc

Merck & Co., Inc.

Sanofi S.A

Johnson & Johnson

Viatris Inc.

Grünenthal 

The Menarini Group